STOCK TITAN

Co-Diagnostics Inc - CODX STOCK NEWS

Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.

Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.

Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.

Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.

Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's CDSCO to manufacture and sell Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics. Utilizing Co-Diagnostics' patented CoPrimer™ technology, these tests aim to accurately detect these mosquito-borne viruses, addressing a significant public health issue as the incidence of dengue has dramatically increased globally. CEO Dwight Egan emphasized the importance of accurate diagnosis for effective treatment and highlighted CoSara's prior approvals for various tests in India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced today that CEO Dwight Egan will join a panel discussion titled "How We Can Defeat the Next Pandemic," hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. 2021 Global Investor Conference. This virtual event is scheduled for September 15, 2021, at 12:00 pm ET. Attendees can register for the conference here. Additionally, Mr. Egan and CFO Brian Brown will present a Healthcare & Biotech On-Demand session available starting September 13, 2021, at 7:00 am ET on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced that its Logix Smart™ COVID-19 Test Kit was utilized by Italian researchers to detect SARS-CoV-2, including mutated strains, through community surveillance testing of discarded saliva samples. The peer-reviewed results were published in Science of the Total Environment. The study involved testing items like plastic cups and bottles across 20 sites in Northern Italy during the COVID-19 peak in early 2021. CEO Dwight Egan emphasized the importance of this study, highlighting the test's effectiveness in identifying viral presence in environmental samples.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will showcase its innovations at the 13th Annual Next Generation Dx Summit from August 24-26, 2021, in Washington, D.C. The summit focuses on critical issues in diagnostics, featuring streams on Point-of-Care Testing (POCT) and Liquid Biopsy. CEO Dwight Egan is scheduled to present on August 25 at 10:30 am ET, discussing a rapid PCR diagnostics platform designed for POCT applications that aim to streamline testing protocols across various environments. More information on the summit can be found at Next Generation Dx.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences
-
Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) reported second-quarter financial results with revenue of $27.4 million, a 13.8% increase year-over-year, driven by the Logix Smart™ COVID-19 Test. Gross profit rose 37.6% to $24.9 million, due to improved production costs. However, operating income fell 19.8% to $11.8 million due to rising sales and marketing expenses. Net income was $9.8 million ($0.33 per share), down from $15.0 million ($0.51 per share) a year earlier. Cash reserves increased to $72.4 million. The company expects Q3 revenue between $23.0 million and $25.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close. The company aims to discuss these results in a conference call at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Co-Diagnostics focuses on molecular diagnostics with a patented technology for developing diagnostic tests based on nucleic acid detection. The results and call are crucial for investors seeking insights into the company's financial performance and future outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced the award of a new patent for its CoPrimer™ technology from South Korea's Intellectual Property Office. This adds to the company's growing portfolio of intellectual property, enhancing the protection of its molecular diagnostic tests. The CoPrimer technology underpins tests like the Logix Smart™ COVID-19 Test kit, which has sold millions globally since the pandemic's onset. Co-Diagnostics emphasizes the durability of its sales model and the significant demand from repeat customers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.15%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (CODX) announced that its Logix Smart™ SARS-CoV-2 DS test has received regulatory authorization as an in vitro diagnostic (IVD) for COVID-19 detection in markets accepting CE markings. This test allows for direct saliva sampling, eliminating the need for RNA extraction, which can reduce costs and increase testing throughput. CEO Dwight Egan emphasized that this innovation could significantly aid in ongoing testing efforts, especially in areas lagging in vaccination rates. The CE marking facilitates immediate sales in the European Community and other global markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present virtually at the 28th International Biodetection Technologies Conference on June 18. The focus will be on point-of-care diagnostics to enhance global health and biodefense. The company's presentation at 12:30 pm ET will detail their rapid PCR testing platform aimed at normalizing daily activities during the COVID-19 pandemic. Additionally, Co-Diagnostics will showcase its products at the CARPHA Health Research Conference from June 16-19, focusing on health issues in the Caribbean region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will release its first-quarter 2021 results on May 13, 2021, after the market close. A conference call and webcast will follow at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Investors can access the event on the company's website. Co-Diagnostics specializes in developing and marketing advanced molecular diagnostic tests using unique technology for detecting nucleic acid molecules, and provides licensing for specific tests across various industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
Co-Diagnostics Inc

Nasdaq:CODX

CODX Rankings

CODX Stock Data

11.66M
31.36M
6.7%
18.02%
0.61%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SALT LAKE CITY